Income Statement (LYELL/IMMUNOPHARMA)

Geode Capital Management LLC raised its position in Lyell Immunopharma, Inc. (NASDAQ:LYEL – Free Report) by 2.9% during the 4th quarter, Holdings Channel.com reports. The firm owned 4,137,264 shares … [+4917 chars]...

Lyell Immunopharma (NASDAQ:LYEL – Get Free Report) is expected to release its Q1 2025 earnings data before the market opens on Monday, May 5th. Analysts expect the company to announce earnings of ($0… [+3213 chars]...

• Presenting new clinical data from Phase 1/2 multi-center clinical trial of LYL314, a next-generation dualtargeting CD19/CD20 CAR T-cell product candidate for the treatment of relapsed and/or … [+25823 chars]...
  Read more

SOUTH SAN FRANCISCO, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patien… [+5042 chars]...

New York, USA, May 13, 2025 (GLOBE NEWSWIRE) -- Metastatic Colorectal Cancer Clinical Trial Pipeline Accelerates as 150+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight Met… [+17406 chars]...

MET-097i, a fully biased, monthly, ultra-long acting GLP-1 receptor agonist, is in three ongoing VESPER Phase 2b trials, with data from VESPER-1 expected in mid-2025 MET-233i, a monthly, ultra-long … [+20907 chars]...